Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic

Canadian Journal of Gastroenterology

Volumn 22, Issue 2, 2008, Pages 133-137

  McLaren, Meaghan ^a   Garber, Gary ^a   Cooper, Curtis ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiviral therapy; HCV; HIV; Liver

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; CANADA; CONSULTATION; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SUBSTANCE ABUSE; SUPERINFECTION; TREATMENT REFUSAL; VIROLOGY; COHORT ANALYSIS; HEALTH CARE DELIVERY; MIDDLE AGED; OUTPATIENT DEPARTMENT; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY;

ADULT; ANTIVIRAL AGENTS; CANADA; COHORT STUDIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; TREATMENT REFUSAL;

EID: 42449150116     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/949582     Document Type: Article

References (27)

1. Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and incidence in Canada, 2005. Canada Communicable Disease Report 2006;32:165-174. (Version current at December 12, 2007).
2. Rosenthal E, Pialoux G, Bernard N, et al, for the GERMIVIC Joint Study Group. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-8.
3. Cooper CL, DeForest J, Gill J, LaLonde R, for the Canadian HIV Trials Network (CTN) Co-Infection Core Group. Barriers preventing liver transplantation in Canadians with HIV-infection - Perceptions of HIV specialists. Can J Gastroenterol 2007;21:179-82.
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
5. Lesens O, Deschênes M, Steben M, Bélanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-8.
6. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36(Suppl 1):S201-9.
7. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-9.
8. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-7.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al, for the APRICOT Study Group. Peginterferon alfa-2a plus ribaviron for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
10. Chung RT, Anderson J, Volberding P, et al, for the AIDS Clinical Trials Group A5071 Study Team. Peginterferon alpha-2a plus ribaviron for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
12. Restrepo A, Johnson TC, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005;12:86-90.
13. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003;36:97-100.
14. Thompson VV, Regland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005;19(Suppl 3):S208-14.
15. Butt A, Justice A, Sanderson M, et al. Rate and predictors of treatment for Hepatitis C (Abstract 862). Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:365.
16. Scott J, Wald A, Kitahata M, et al. HCV is infrequently evaluated and treated in an urban HIV clinic population (Astract 882). Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:373.
17. Mehta SH, Lucas G, Torbenson M, et al. Barriers to referral for hepatisis C virus care among HIV/HCV-co-infected patient in an Urban HIV clinic (Abstract 884). Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:374.
18. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003 36:97-100.
19. Restrepo A, Johnson TC, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005;12:86-90.
20. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006;30:1520-6.
21. Shafran SD, Manshinter LD, Lindemulder A, et al. Eligibility of HIV-HCV coinfected adults for HCV treatment. Can J Infect Dis 2004;15:46A. (Abst)
22. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clin Infect Dis 2002:34:984-90.
23. Clanon KA, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV Clinic. Clin Infect Dis 2005;40(Suppl 5):S362-6.
24. Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis 2005;41(Suppl 1):S83-8.
25. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005;40(Suppl 5):S355-61.
26. Balfour L, Cooper C, Tasca GA, Kane M, Kowal J, Garber G. Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. Can J Public Health 2004;95:272-7.
27. Balfour L, Kowal J, Silverman A, et al. A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006;18:830-8.